US20060258686A1
(en)
*
|
1998-05-29 |
2006-11-16 |
Cheresh David A |
Method of treatment of myocardial infarction
|
US20030130209A1
(en)
*
|
1999-12-22 |
2003-07-10 |
Cheresh David A. |
Method of treatment of myocardial infarction
|
ATE494388T1
(de)
|
1999-01-13 |
2011-01-15 |
Univ New York State Res Found |
Neues verfahren zum erschaffen von proteinkinase- inhibitoren
|
US7223724B1
(en)
*
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
ATE253918T1
(de)
|
1999-12-08 |
2003-11-15 |
Centre Nat Rech Scient |
Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
|
NZ518077A
(en)
*
|
2000-08-04 |
2003-11-28 |
Human Genome Sciences Inc |
Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
|
MXPA03008560A
(es)
*
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
EP2228389B1
(en)
*
|
2001-04-13 |
2015-07-08 |
Human Genome Sciences, Inc. |
Antibodies against vascular endothelial growth factor 2
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
WO2002083849A2
(en)
*
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
CA2464214C
(en)
*
|
2001-10-22 |
2011-02-08 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
BR0313078A
(pt)
|
2002-08-06 |
2005-07-12 |
Astrazeneca Ab |
Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou de um sal deste farmaceuticamente aceitável
|
KR20110010824A
(ko)
|
2003-01-14 |
2011-02-07 |
아레나 파마슈티칼스, 인크. |
대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료
|
AU2004221812B2
(en)
|
2003-03-19 |
2010-02-18 |
Exelixis Inc. |
Tie-2 modulators and methods of use
|
US20050008640A1
(en)
*
|
2003-04-23 |
2005-01-13 |
Wendy Waegell |
Method of treating transplant rejection
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
JP4920410B2
(ja)
*
|
2003-07-14 |
2012-04-18 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
|
DE10344223A1
(de)
*
|
2003-09-24 |
2005-04-21 |
Merck Patent Gmbh |
1,3-Benzoxazolylderivate als Kinase-Inhibitoren
|
GB0401334D0
(en)
*
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
EP1730148A4
(en)
*
|
2004-02-03 |
2009-08-19 |
Abbott Lab |
USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
|
WO2006068760A2
(en)
*
|
2004-11-19 |
2006-06-29 |
The Regents Of The University Of California |
Anti-inflammatory pyrazolopyrimidines
|
DOP2006000009A
(es)
*
|
2005-01-13 |
2006-08-15 |
Arena Pharm Inc |
Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
|
NZ560448A
(en)
*
|
2005-02-16 |
2009-08-28 |
Anacor Pharmaceuticals Inc |
Boron-containing small molecules
|
JP5147401B2
(ja)
*
|
2005-09-06 |
2013-02-20 |
塩野義製薬株式会社 |
Pgd2受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
|
SI1951724T1
(sl)
*
|
2005-11-17 |
2011-09-30 |
Osi Pharmaceuticals Llc |
Kondenzirani biciklični mTOR inhibitorji
|
HUE030235T2
(en)
|
2005-12-13 |
2017-04-28 |
Incyte Holdings Corp |
Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
|
EP1981888A4
(en)
*
|
2006-01-13 |
2010-10-13 |
Pharmacyclics Inc |
TYROSINE KINASE INHIBITORS AND USES THEREOF
|
WO2007087395A2
(en)
*
|
2006-01-25 |
2007-08-02 |
Osi Pharmaceuticals, Inc. |
UNSATURATED mTOR INHIBITORS
|
BRPI0708615A2
(pt)
*
|
2006-03-07 |
2011-06-07 |
Array Biopharma Inc |
compostos de pirazol heterobicìclicos e métodos de uso
|
US7585868B2
(en)
|
2006-04-04 |
2009-09-08 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
|
US20080125587A1
(en)
*
|
2006-05-25 |
2008-05-29 |
Chimmanamada Dinesh U |
Synthesis of triazole compounds that modulate HSP90 activity
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
US20080114063A1
(en)
*
|
2006-08-16 |
2008-05-15 |
Action Medicines |
Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases
|
EP2526933B1
(en)
|
2006-09-22 |
2015-02-25 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
ES2403546T3
(es)
*
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
CA2672494A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Nps Pharmaceuticals, Inc. |
Use of d-serine derivatives for the treatment of anxiety disorders
|
JP2010514692A
(ja)
|
2006-12-20 |
2010-05-06 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
|
DK2099442T3
(en)
*
|
2006-12-26 |
2015-02-16 |
Pharmacyclics Inc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
EP2125895B1
(en)
|
2007-02-02 |
2015-04-08 |
Vegenics Pty Ltd |
Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
WO2008153701A1
(en)
*
|
2007-05-24 |
2008-12-18 |
Schering Corporation |
Compounds for inhibiting ksp kinesin activity
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
US20110160232A1
(en)
|
2007-10-04 |
2011-06-30 |
Pingda Ren |
Certain chemical entities and therapeutic uses thereof
|
CA2709879A1
(en)
*
|
2007-12-19 |
2009-06-25 |
The Scripps Research Institute |
Anilides and analogs as rho kinase inhibitors
|
WO2009079008A1
(en)
*
|
2007-12-19 |
2009-06-25 |
Yangbo Feng |
Benzopyrans and analogs as rho kinase inhibitors
|
WO2009088990A1
(en)
|
2008-01-04 |
2009-07-16 |
Intellikine, Inc. |
Certain chemical entities, compositions and methods
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
EP2276763A1
(en)
*
|
2008-03-19 |
2011-01-26 |
OSI Pharmaceuticals, Inc. |
Mtor inhibitor salt forms
|
US20100101977A1
(en)
*
|
2008-06-05 |
2010-04-29 |
United Comb & Novelty Corporation |
Stackable Packaging For Lipped Containers
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
CN102124009B
(zh)
|
2008-07-08 |
2014-07-23 |
因特利凯公司 |
激酶抑制剂及其使用方法
|
JP5369183B2
(ja)
|
2008-07-16 |
2013-12-18 |
ファーマサイクリックス,インク. |
固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
DK2358720T3
(en)
*
|
2008-10-16 |
2016-06-06 |
Univ California |
Heteroarylkinaseinhibitorer fused-ring
|
EP2352501B1
(en)
*
|
2008-11-03 |
2014-01-01 |
ChemoCentryx, Inc. |
Compounds for use in the treatment of osteoporosis
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
US8426428B2
(en)
*
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
WO2010129816A2
(en)
|
2009-05-07 |
2010-11-11 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
EA020494B1
(ru)
|
2009-05-22 |
2014-11-28 |
Инсайт Корпорейшн |
3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
JP6073677B2
(ja)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
縮合複素環式化合物およびそれらの使用
|
JP5819831B2
(ja)
|
2009-08-17 |
2015-11-24 |
インテリカイン, エルエルシー |
複素環式化合物およびそれらの使用
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
EP2483407A2
(en)
|
2009-09-30 |
2012-08-08 |
President and Fellows of Harvard College |
Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
EP2947073B1
(en)
*
|
2009-10-22 |
2019-04-03 |
Fibrotech Therapeutics Pty Ltd |
Fused ring analogues of anti-fibrotic agents
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
EP3378854B1
(en)
|
2010-01-27 |
2022-12-21 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
AU2011215645A1
(en)
*
|
2010-02-11 |
2012-09-20 |
Vanderbilt University |
Benzisoxazoles and azabenzisoxazoles as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
MX347851B
(es)
|
2010-03-10 |
2017-05-16 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
|
WO2011133520A1
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
WO2011146882A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
EP3087972A1
(en)
|
2010-05-21 |
2016-11-02 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
EP2578573A4
(en)
*
|
2010-05-24 |
2014-08-06 |
Toa Eiyo Ltd |
CONDENSATE IMIDAZOLE DERIVATIVE
|
CA3154024C
(en)
|
2010-06-03 |
2024-02-27 |
Pharmacyclics Llc |
Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
|
EP2590982B1
(en)
*
|
2010-07-09 |
2017-08-23 |
The Walter and Eliza Hall Institute of Medical Research |
Protein kinase inhibitors and methods of treatment
|
US10894787B2
(en)
|
2010-09-22 |
2021-01-19 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
EP2637669A4
(en)
|
2010-11-10 |
2014-04-02 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and their use
|
SG190839A1
(en)
|
2010-11-19 |
2013-07-31 |
Incyte Corp |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
NZ612909A
(en)
|
2011-01-10 |
2015-09-25 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
AR085397A1
(es)
|
2011-02-23 |
2013-09-25 |
Intellikine Inc |
Combinacion de inhibidores de quinasa y sus usos
|
AR086983A1
(es)
|
2011-06-20 |
2014-02-05 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
ES2624981T3
(es)
|
2011-07-01 |
2017-07-18 |
Dana-Farber Cancer Institute, Inc. |
Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
|
JP2014520863A
(ja)
|
2011-07-13 |
2014-08-25 |
ファーマサイクリックス,インク. |
Bruton型チロシンキナーゼの阻害剤
|
TWI565709B
(zh)
|
2011-07-19 |
2017-01-11 |
英菲尼提製藥股份有限公司 |
雜環化合物及其用途
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
HRP20212021T1
(hr)
|
2011-07-19 |
2022-04-01 |
Merck Sharp & Dohme B.V. |
4-IMIDAZOPIRIDAZIN-1-iL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDI KAO INHIBITORI BTK
|
EP2548877A1
(en)
*
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
AR091790A1
(es)
|
2011-08-29 |
2015-03-04 |
Infinity Pharmaceuticals Inc |
Derivados de isoquinolin-1-ona y sus usos
|
JP6342805B2
(ja)
*
|
2011-09-02 |
2018-06-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
置換ピラゾロ[3,4−d]ピリミジンおよびその用途
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
US9492423B2
(en)
|
2011-09-13 |
2016-11-15 |
Pharmacyclics Llc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
AU2012332421A1
(en)
|
2011-11-02 |
2014-06-05 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
|
AU2012332424A1
(en)
|
2011-11-02 |
2014-06-05 |
Synta Pharmaceuticals Corp. |
Combination therapy of Hsp90 inhibitors with platinum-containing agents
|
US9402831B2
(en)
|
2011-11-14 |
2016-08-02 |
Synta Pharmaceutical Corp. |
Combination therapy of HSP90 inhibitors with BRAF inhibitors
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
JP6083818B2
(ja)
|
2011-11-18 |
2017-02-22 |
ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited |
ムスカリンm1受容体アゴニスト
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
EP2809673B1
(en)
*
|
2012-01-31 |
2016-11-02 |
Nanjing Allgen Pharma Co. Ltd. |
Spirocyclic molecules as bruton's tyrosine kinase inhibitors
|
JP2015514686A
(ja)
|
2012-02-29 |
2015-05-21 |
コヨーテ・ファーマシューティカルズ・インコーポレイテッドCoyote Pharmaceuticals, Inc. |
Gga及びそのgga誘導体組成物並びにこれらを含む麻痺状態を含めた神経変性疾患を治療する方法
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AR091079A1
(es)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
|
CA2874211A1
(en)
*
|
2012-05-31 |
2013-12-05 |
Pharmascience Inc. |
Protein kinase inhibitors
|
US9296753B2
(en)
|
2012-06-04 |
2016-03-29 |
Pharmacyclics Llc |
Crystalline forms of a Bruton's tyrosine kinase inhibitor
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
GB201211309D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Fujifilm Mfg Europe Bv |
Process for preparing membranes
|
MX2015001081A
(es)
|
2012-07-24 |
2015-10-14 |
Pharmacyclics Inc |
Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
|
JP6327713B2
(ja)
*
|
2012-07-27 |
2018-05-23 |
国立研究開発法人理化学研究所 |
急性骨髄性白血病の治療又は再発抑制剤
|
SG11201502331RA
(en)
|
2012-09-26 |
2015-04-29 |
Univ California |
Modulation of ire1
|
US9119808B1
(en)
|
2012-10-08 |
2015-09-01 |
Coyote Pharmaceuticals, Inc. |
Treating neurodegenerative diseases with GGA or a derivative thereof
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
USRE48175E1
(en)
*
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
CN104854107A
(zh)
|
2012-11-15 |
2015-08-19 |
药品循环公司 |
作为激酶抑制剂的吡咯并嘧啶化合物
|
KR20220162825A
(ko)
|
2012-11-15 |
2022-12-08 |
인사이트 홀딩스 코포레이션 |
룩솔리티니브의 서방성 제형
|
WO2014113942A1
(en)
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
ES2694299T3
(es)
|
2013-02-07 |
2018-12-19 |
Heptares Therapeutics Limited |
Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
|
AU2014225938B2
(en)
|
2013-03-06 |
2018-07-19 |
Incyte Holdings Corporation |
Processes and intermediates for making a JAK inhibitor
|
EP2964260A2
(en)
|
2013-03-06 |
2016-01-13 |
F. Hoffmann-La Roche AG |
Methods of treating and preventing cancer drug resistance
|
TWI629275B
(zh)
*
|
2013-03-13 |
2018-07-11 |
賽諾菲公司 |
N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
EP2976086B1
(en)
|
2013-03-22 |
2020-10-14 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
EP3027192A4
(en)
|
2013-08-02 |
2017-03-22 |
Pharmacyclics, LLC |
Methods for the treatment of solid tumors
|
KR20160045081A
(ko)
|
2013-08-07 |
2016-04-26 |
인사이트 코포레이션 |
Jak1 억제제용 지속 방출 복용 형태
|
CA2920534A1
(en)
|
2013-08-12 |
2015-02-19 |
Pharmacyclics Llc |
Methods for the treatment of her2 amplified cancer
|
SG11201602421VA
(en)
|
2013-09-30 |
2016-04-28 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
EA201690713A1
(ru)
|
2013-10-04 |
2016-08-31 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения и их применения
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
KR102452866B1
(ko)
|
2013-10-25 |
2022-10-07 |
파마싸이클릭스 엘엘씨 |
이식편 대 숙주 질환의 치료 및 예방 방법
|
AU2014358868A1
(en)
|
2013-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Therapeutic combination of a PI3K inhibitor and a BTK inhibitor
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
NZ721617A
(en)
*
|
2014-02-03 |
2018-01-26 |
Cadila Healthcare Ltd |
Heterocyclic compounds
|
CN114404427A
(zh)
|
2014-02-13 |
2022-04-29 |
配体药物公司 |
前药化合物及其用途
|
CA2943075C
(en)
|
2014-03-19 |
2023-02-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
GB201410430D0
(en)
*
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック, インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
US9949971B2
(en)
|
2014-06-17 |
2018-04-24 |
Acerta Pharma B.V. |
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
|
AU2015296215A1
(en)
|
2014-08-01 |
2017-03-23 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
WO2016022942A1
(en)
|
2014-08-07 |
2016-02-11 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
DK3179991T3
(da)
|
2014-08-11 |
2021-12-06 |
Acerta Pharma Bv |
Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
US10196397B2
(en)
|
2014-11-19 |
2019-02-05 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of ibrutinib
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2016106628A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
MX2021011472A
(es)
|
2015-01-06 |
2022-08-17 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
WO2016115869A1
(zh)
*
|
2015-01-21 |
2016-07-28 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
CN105481862B
(zh)
*
|
2015-01-21 |
2018-08-21 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
SG11201707122QA
(en)
|
2015-03-03 |
2017-09-28 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
MA41828A
(fr)
*
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
WO2016161248A1
(en)
*
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
KR102603199B1
(ko)
|
2015-06-22 |
2023-11-16 |
아레나 파마슈티칼스, 인크. |
S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염
|
LT3613745T
(lt)
|
2015-07-02 |
2021-10-11 |
Acerta Pharma B.V. |
(s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamido kietosios formos ir vaistinės formos
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
NZ740616A
(en)
|
2015-09-14 |
2023-05-26 |
Infinity Pharmaceuticals Inc |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
JP7337502B2
(ja)
|
2015-09-16 |
2023-09-04 |
ロクソ オンコロジー, インコーポレイテッド |
がんの治療のためのbtk阻害剤としてのピラゾロピリミジン誘導体
|
UA127863C2
(uk)
|
2015-12-16 |
2024-01-31 |
Локсо Онколоджі, Інк. |
Сполуки, які можна застосовувати як інгібітори кінази
|
US10662187B2
(en)
*
|
2016-01-21 |
2020-05-26 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
CA3016364A1
(en)
|
2016-03-03 |
2017-09-08 |
Bayer Pharma Aktiengesellschaft |
New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
|
CN109071455B
(zh)
|
2016-03-11 |
2022-08-02 |
嘉兴和剂药业有限公司 |
用于调节布鲁顿酪氨酸激酶的化合物及方法
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
JP2019518006A
(ja)
|
2016-04-29 |
2019-06-27 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Myd88変異型疾患における治療標的としてのhck
|
CN105820184A
(zh)
*
|
2016-05-06 |
2016-08-03 |
蚌埠中实化学技术有限公司 |
一种4-苯氧基苯硼酸的制备方法
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN109640999A
(zh)
|
2016-06-24 |
2019-04-16 |
无限药品股份有限公司 |
组合疗法
|
GB201617454D0
(en)
|
2016-10-14 |
2016-11-30 |
Heptares Therapeutics Limited |
Pharmaceutical compounds
|
AU2017382406A1
(en)
|
2016-12-23 |
2019-04-18 |
Arvinas Operations, Inc. |
EGFR proteolysis targeting chimeric molecules and associated methods of use
|
KR20190115451A
(ko)
|
2017-02-03 |
2019-10-11 |
세르타 테라퓨틱스 피티와이 엘티디. |
항-섬유성 화합물
|
WO2018151873A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
WO2018222795A1
(en)
|
2017-06-01 |
2018-12-06 |
Bristol-Myers Squibb Company |
Substituted nitrogen containing compounds
|
US11952572B2
(en)
|
2017-08-14 |
2024-04-09 |
Epizyme, Inc. |
Methods of treating cancer by inhibiting SETD2
|
CN107550905B
(zh)
*
|
2017-09-11 |
2020-07-17 |
浙江永宁药业股份有限公司 |
多取代吡咯并吡啶类化合物的药物用途及其制备方法
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
CN111699031B
(zh)
*
|
2017-12-27 |
2022-10-28 |
株式会社新生能源研究 |
Co2除去方法和装置
|
EP3737676B1
(en)
|
2018-01-09 |
2024-03-06 |
Ligand Pharmaceuticals, Inc. |
Acetal compounds and therapeutic uses thereof
|
TWI797242B
(zh)
|
2018-01-30 |
2023-04-01 |
美商英塞特公司 |
製備jak抑制劑之方法及中間物
|
MX2022012285A
(es)
|
2018-03-30 |
2023-08-15 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
GB201810239D0
(en)
|
2018-06-22 |
2018-08-08 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
WO2020079652A1
(en)
|
2018-10-17 |
2020-04-23 |
Insilico Medicine Hong Kong Limited |
Kinase inhibitors
|
BR112021009106A2
(pt)
|
2018-11-12 |
2021-08-10 |
Debiopharm International S.A. |
compostos antibióticos, métodos de fabricação dos mesmos, composições farmacêuticas que os contêm e seus usos
|
GB201819960D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药(上海)有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
US20220153734A1
(en)
*
|
2019-02-27 |
2022-05-19 |
Optikira, LLC |
Pyrazolopyridine Compounds For IRE1 Inhibition
|
KR20220016049A
(ko)
|
2019-05-31 |
2022-02-08 |
스촨 하이스코 파마수티컬 씨오., 엘티디 |
Btk 억제제 고리 유도체, 이의 제조 방법 및 이의 약제학적 응용
|
CN110511225B
(zh)
*
|
2019-08-19 |
2023-07-18 |
杭州中美华东制药有限公司 |
一种伊布替尼中间体的合成方法
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
WO2021184154A1
(en)
|
2020-03-16 |
2021-09-23 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022081512A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Synubi Pharmaceuticals Llc |
Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
|
IL302807A
(en)
|
2020-11-18 |
2023-07-01 |
Deciphera Pharmaceuticals Llc |
GCN2 and PERK kinase inhibitors and methods of using them
|
CN114751927B
(zh)
*
|
2022-03-08 |
2023-10-31 |
中山大学 |
一种硼酸化合物、制备方法及用途
|
CN115124486A
(zh)
*
|
2022-07-07 |
2022-09-30 |
武汉理工大学 |
苯并噁唑衍生物及其制备方法与应用
|